Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer

European Journal of Cancer(2024)10.1016/j.ejca.2024.113914Source: DataRank Database

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer is a research paper published in European Journal of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.33)OA: greenTopics (36)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (32)

Yan Yang ORCID,Yasmine Baca ORCID,Joshua Millstein ORCID,Tadamichi Denda ORCID,Fang‐Shu Ou ORCID

Live enrichment

PubMed:38359495 PMC:PMC11323978 OpenAlex:https://openalex.org/W4391722881

NCI NIH HHS

Grant: U10 CA180888

NCI NIH HHS

Grant: U10 CA180882

NCI NIH HHS

Grant: UG1 CA233373

NCI NIH HHS

Grant: UG1 CA233163

NCI NIH HHS

Grant: UG1 CA239758

NCI NIH HHS

Grant: U10 CA180821

NCI NIH HHS

Grant: UG1 CA180830

NCI NIH HHS

Grant: P30 CA014089

Gloria Borges Wunderglo Foundation

National Cancer Institute

Dhont Family Foundation

FWCI

0.33

Citation Percentile

0.5%

Citation Trend

2024

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11323978/pdf/nihms-1969719.pdf

publisherhttps://api.elsevier.com/content/article/PII:S095980492400090X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S095980492400090X?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11323978

Fields of Study

Heat shock proteins researchColorectal Cancer Treatments and StudiesPARP inhibition in cancer therapy

MeSH Terms

BevacizumabCetuximabAntineoplastic Combined Chemotherapy ProtocolsColonic NeoplasmsHumansPhenylurea CompoundsPyridinesRectal NeoplasmsRetrospective StudiesColorectal NeoplasmsGene ExpressionCell Cycle ProteinsMolecular ChaperonesChaperonins

Keywords

MedicineInternal medicineOncologyColorectal cancerRegorafenibBevacizumabCDC37Hazard ratioQuartileCetuximabCancerKinaseConfidence intervalMAPK/ERK pathwayBiologyChemotherapyChaperoneHSP90Targeted Therapy

Sustainable Development Goals

SDG 0: Good health and well-being